Patients With Follicular Lymphoma (fl) in Maintained Complete Response (cr) at 30 Months Show a Survival Similar to a Sex‐ and Age‐matched Spanish General Population
Year: 2017
Type: article
Study design: Observational Study
Abstract: 73% of young patients vs 66%, p = 0.0021).The two groups had similar CR24 (32% vs 29%, p = 0.32), CR30 (31% vs 30%, p = 0.57), 5-year estimates for PFS of 44% (95% CI = 41-49 for young patients and 43-46 for patients 40-60) (p = 0.30) and TTP (median TTP 3.9 y vs 4.0 y, HR = 0.96, 95% CI = 0.86-1.08,p = 0.52).OS was significantly higher for young patients with 5-year estimates of 88% (95% CI = 85-90) versus 84% (95% CI = 83-86) (p = 0.003).After adjusting with FLIPI risk group, rituximab use and PS, age <40 was a significant predictor of OS, but not of PFS, TTP or achievement of CR30.Of note, for patients having received rituximab in their first line treatment (n = 1846), patients <40 (n = 265) and patients aged 40-60 (n = 1581) had respective 5-year estimates for PFS of 54% (95% CI = 48-62) and 54% (95% CI = 51-57) (p = 0.70) and for OS of 96% (95% CI = 94-99) versus 90% (95% CI = 88-91) (p = 0.0004) (Figure ).No significant difference in OS was observed between the 2 groups for patients not having received rituximab in first line.These data suggest that among patients treated with rituximab, despite an identical PFS, survival outcomes were statistically higher in the <40 group compared to 40-60.Conclusions: This study reports the clinical characteristics and outcomes in the most important cohort of young patients aged <40 with first-line FL.Age <40 y did not appear to influence the treatment outcome, but was associated with a significantly longer OS.
Source: Hematological Oncology
DOI: 10.1002/hon.2438_90
Authors: L. Magnano, S. Alonso‐Alvarez, M. Alcoceba, A. Rivas‐Delgado, A. Muntañola, M. Andrade‐Campos, G. Rodriguez, J. Sancho, S. Mercadal, A. Salar, R. Arranz, M. Terol, A. Jiménez‐Ubieto, S. González de Villambrosía, J. Bello, L. López, S. Novelli, E. De Cabo, M. Infante, E. Pardal, M. Canals, M. González, A. Martín, M. Caballero, A. López‐Guillermo
Institutions: Hospital Clínic de Barcelona, Complejo Hospitalario de Salamanca, University Hospital Mútua de Terrassa, Mútua Terrassa, Hospital Universitario Miguel Servet, Hospital Universitario Virgen del Rocío, Duran i Reynals Hospital, Hospital Del Mar, Hospital Universitario de La Princesa, Hospital Clínico Universitario de Valencia, Hospital Universitario 12 De Octubre, Marqués de Valdecilla University Hospital, MD Anderson Cancer Center Madrid, Hospital de Sant Pau, Hospital El Bierzo, Hospital Universitario Infanta Leonor, Hospital Virgen del Puerto, Hospital Universitario La Paz
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Keywords: follicular lymphoma, complete response, age at diagnosis, survival, progression-free survival, time to progression, overall survival, rituximab, prognostic factors, young patients, general population comparison, first-line therapy, Spanish patients, mantle cell lymphoma, B-cell lymphoma, prognostic score
Open Access status: bronze
OpenAlex ID: W2621655893
